Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • New treatment methods: DNA origami-based nanodevices precisely control immune response - 24/04/2025 Hydroborierung_synthetische-Immunologie.png

    Bottom-up synthetic immunology for novel therapeutic approaches

    Modern therapies for combating cancer and infectious diseases increasingly leverage the body’s own immune system. Several research groups at Heidelberg University are using innovative bottom-up approaches in synthetic immunology to develop new treatment methods that can control the immune response more precisely than previously possible.

    https://www.gesundheitsindustrie-bw.de/en/article/news/bottom-synthetic-immunology-novel-therapeutic-approaches
  • Intestinal peptide heals lung - 14/10/2020 Die Immuntherapie (ICI)  aktiviert Effektor-T-Zellen  und reduziert auf der anderen Seite regulatorische T-zellen, um den Tumor zu besiegen (schwarze Zellen). Die durch die Immuntherapie ausgelöste Lungenentzündung wird mit Steroidtherapie (Cortison) oder mit inhaliertem VIP (vasoaktives intestinales Peptid) behandelt. Unter VIP kommt es zur Dämpfung der Entzündung.

    Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

    If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

    https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
  • Press release - 17/10/2023

    BioCopy and YUMAB announce partnership for development of innovative safeTY-engager® platform

    The development of highly specific T-cell engagers directed against pHLA tumor targets will be quick and easy. BioCopy's innovative pHLA screening technology characterizes drug candidates in great depth for their specific binding against the desired pHLA tumor target. YUMAB develops highly specific antibodies with their advanced antibody technologies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-und-yumab-verkuenden-partnerschaft-fuer-entwicklung-innovativer-safety-engager-r-plattform
  • Dossier - 13/04/2015 In Germany, young girls can now protect themselves from cervical cancer. (Photo: NCI)

    Boosting the immune system can improve cancer prevention and treatment

    The activation of the body’s immune system to fight cancer is not only a promising therapeutic concept, but is already used in medical practice. The first immunotherapies have been approved and many more are either in the experimental stages or already undergoing clinical testing. Vaccines to prevent certain types of cancer are already being used successfully around the world.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/boosting-the-immune-system-can-improve-cancer-prevention-and-treatment
  • Press release - 03/05/2024

    Newly discovered mechanism of T-cell control can interfere with cancer immunotherapies

    Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-mechanism-t-cell-control-can-interfere-cancer-immunotherapies
  • Press release - 04/07/2024

    Antibody can improve immune cell therapy against leukemia

    Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-can-improve-immune-cell-therapy-against-leukemia
  • Press release - 06/02/2024

    New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

    BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a collaboration bet- ween both institutions and researchers at the German Cancer Research Center (DKFZ), the Heidelberg Uni- versity, and the Helmholtz Institute for Translational Oncology (HI-TRON).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/neue-t-finder-plattform-liefert-tiefe-einblicke-t-zell-antwort-auf-neuartigen-krebsimpfstoff
  • Press release - 14/09/2021

    Bridging antibodies plus enhancer can destroy breast cancer cells

    Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have developed antibodies that have two antigen-binding sites and can couple cancer cells with effector cells of the immune system. In laboratory tests, these bridging antibodies, together with an enhancer antibody, were able to specifically mobilize the body's own immune defenses and destroy breast cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/Bridging-antibodies-plus-enhancer-can-destroy-breast-cancer-cells
  • Predicting the success of cancer treatment - 20/06/2023 Graphical representation of the course of intestinal microbiome analysis in CAR-T cell therapy patients.

    Focusing on gut microbiome for CAR T-cell therapy

    Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/news/focusing-gut-microbiome-car-t-cell-therapy
  • New method for analysing blood samples - 26/11/2020 Bildschirmfoto_2020-10-30_um_11.46.25.png

    Personalised therapy monitoring for malignant melanomas

    Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
  • Press release - 12/06/2025

    BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

    Acquisition will strengthen the mRNA-based cancer immunotherapy candidates, marking BioNTech’s milestone in its oncology strategy. Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing. All-stock acquisition has potential to create value for both companies’ shareholders given their complementary capabilities, focus on mRNA, and shared vision.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biontech-announces-strategic-transaction-acquire-curevac-public-exchange-offer
  • Press release - 25/10/2023

    Epigenetically acting drugs could support cancer immunotherapy

    Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/epigenetically-acting-drugs-could-support-cancer-immunotherapy
  • Press release - 06/11/2023

    Improving the efficacy of cancer immunotherapy with modified CAR-T cells

    CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments are unsuccessful. A limiting factor of this very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/improving-efficacy-cancer-immunotherapy-modified-car-t-cells
  • Press release - 24/03/2021

    Liver cancer: which patients benefit from immunotherapy?

    Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/liver-cancer-which-patients-benefit-immunotherapy
  • Press release - 25/05/2021

    How “paralyzed” immune cells can be reactivated against brain tumors

    Brain tumor cells with a certain common mutation reprogram invading immune cells. This leads to the paralysis of the body's immune defense against the tumor in the brain. Researchers from Heidelberg, Mannheim, and Freiburg discovered this mechanism and at the same time identified a way of reactivating the paralyzed immune system to fight the tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-paralyzed-immune-cells-can-be-reactivated-against-brain-tumors
  • Press release - 20/12/2021

    Immune microenvironment as a risk factor for colorectal cancer in Lynch syndrome

    Researchers at Heidelberg University Hospital (UKHD), the German Cancer Research Center (DKFZ) and at the National Center for Tumor Diseases (NCT) Heidelberg have demonstrated for the first time that there is a link between the development of colorectal cancer in individuals with Lynch syndrome and the composition of immune cells in the colorectal mucosa.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/immune-microenvironment-risk-factor-colorectal-cancer-lynch-syndrome
  • Press release - 23/05/2023

    B cells promote liver cancer with dangerous dual strategy

    Inflammatory fatty liver disease (NASH, non alcoholic steatohepatitis ) and the resulting liver cancer are driven by autoaggressive T cells. Scientists from the German Cancer Research Center (DKFZ) now show what ist behind this destructive behavior. In both mice and humans with NASH, they found increased numbers of activated B cells in the gastrointestinal tract.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/b-cells-promote-liver-cancer-dangerous-dual-strategy
  • Press release - 16/05/2023

    Mast cells have an important impact on the development of chronic myeloid leukemia

    Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20 percent of all adult leukemia cases. A research team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg has now demonstrated for the first time that mast cells play a crucial role in the development of CML.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mast-cells-have-important-impact-development-chronic-myeloid-leukemia
  • Press release - 03/04/2025

    Heinz Maier-Leibnitz Prize for Lukas Bunse

    Germany's most important award for young scientists honors the development of immunotherapies against malignant brain tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heinz-maier-leibnitz-prize-lukas-bunse
  • Press release - 22/05/2025

    Six Clusters of Excellence for the University of Tübingen

    Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/six-clusters-excellence-university-tubingen
  • Innovative Therapies - 20/08/2020 Das Bild zeigt eine pipettierende Frau in Nahaufnahme. Symbolbild für analytische Dienstleistungen des portraitierten Unternehmens.

    Labor Dr. Merk is fully committed to viral therapies

    Labor Dr. Merk & Kollegen is reorienting its business towards viral therapeutics. With this change of strategy, the company, which has decades of expertise in virology, wants to position itself in a timely fashion in the growing new market for advanced therapy medicinal products (ATMP). In gene and virotherapies (oncolytic viruses), tumour vaccines and CAR-T cell therapies, viruses are essential as vectors, killers of tumour cells or…

    https://www.gesundheitsindustrie-bw.de/en/article/news/labor-dr-merk-fully-committed-viral-therapies
  • Press release - 17/05/2021

    New findings in genome research

    The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-genome-research
  • Press release - 15/11/2021

    Using T cell to target malignant brain tumors

    Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-t-cell-target-malignant-brain-tumors
  • Press release - 07/12/2021

    New approach developed to predict response of immunotherapies in lung cancer

    At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-developed-predict-response-immunotherapies-lung-cancer
  • Press release - 07/12/2021

    Moderate immune response is more effective against leukemia

    The development of immunotherapies against blood cancer could be more successful if T cells are activated moderately rather than excessively. Scientists from the German Cancer Research Center have now been able to show this in mice: If the researchers blocked a cytokine that slows down the immune system, the T cells became exhausted and failed in the fight against leukemia.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/moderate-immune-response-more-effective-against-leukemia

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search